AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Tarlatamab for Small Cell Lung Cancer: How DLL3-Targeted Therapy Works
By Daniel Ricardo Carrizosa, MD, MS
Small cell lung cancer has long been considered one of the more difficult diagnoses in thoracic oncology.
Tarlatamab for Small Cell Lung Cancer: How DLL3-Targeted Therapy Works
By Daniel Ricardo Carrizosa, MD, MS
Small cell lung cancer has long been considered one of the more difficult diagnoses in thoracic oncology.
Tarlatamab for Small Cell Lung Cancer: How DLL3-Targeted Therapy Works
By Daniel Ricardo Carrizosa, MD, MS
Small cell lung cancer has long been considered one of the more difficult diagnoses in thoracic oncology.
A New Antibody-Drug Conjugate and a Biomarker Reality Check for Small Cell Lung Cancer
By Mark Alan Klein, MD
Small cell lung cancer has trailed its non-small cell counterpart in new drug approvals for years, and at this year's ASCO meeting there were no studies presented that affect first-line treatments at this time.
A New Antibody-Drug Conjugate and a Biomarker Reality Check for Small Cell Lung Cancer
By Mark Alan Klein, MD
Small cell lung cancer has trailed its non-small cell counterpart in new drug approvals for years, and at this year's ASCO meeting there were no studies presented that affect first-line treatments at this time.
A New Antibody-Drug Conjugate and a Biomarker Reality Check for Small Cell Lung Cancer
By Mark Alan Klein, MD
Small cell lung cancer has trailed its non-small cell counterpart in new drug approvals for years, and at this year's ASCO meeting there were no studies presented that affect first-line treatments at this time.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
CAR-T Cell Therapy and Bispecific Antibodies Are Transforming Acute Lymphoblastic Leukemia
By Thomas Knight, MD
Ten years ago, ALL was a chemotherapy-heavy disease with poor long-term survival for many patient groups. That has changed dramatically.
CAR-T Cell Therapy and Bispecific Antibodies Are Transforming Acute Lymphoblastic Leukemia
By Thomas Knight, MD
Ten years ago, ALL was a chemotherapy-heavy disease with poor long-term survival for many patient groups. That has changed dramatically.
CAR-T Cell Therapy and Bispecific Antibodies Are Transforming Acute Lymphoblastic Leukemia
By Thomas Knight, MD
Ten years ago, ALL was a chemotherapy-heavy disease with poor long-term survival for many patient groups. That has changed dramatically.
Next-Generation Cellular and T-Cell Engaging Therapies Are Reshaping Multiple Myeloma Care
By Cindy Varga, MD
Multiple myeloma treatment is shifting toward earlier CAR-T use, dual-antigen bispecifics, and next-gen platforms (allogeneic, in vivo, mRNA) to expand global access.
Next-Generation Cellular and T-Cell Engaging Therapies Are Reshaping Multiple Myeloma Care
By Cindy Varga, MD
Multiple myeloma treatment is shifting toward earlier CAR-T use, dual-antigen bispecifics, and next-gen platforms (allogeneic, in vivo, mRNA) to expand global access.
Next-Generation Cellular and T-Cell Engaging Therapies Are Reshaping Multiple Myeloma Care
By Cindy Varga, MD
Multiple myeloma treatment is shifting toward earlier CAR-T use, dual-antigen bispecifics, and next-gen platforms (allogeneic, in vivo, mRNA) to expand global access.
Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Permission to Pause Treatment
By Peter Silberstein, MD
Four developments from this year's ASCO meeting reshape decision-making across the prostate cancer spectrum, from the operating room to the metastatic setting.
Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Permission to Pause Treatment
By Peter Silberstein, MD
Four developments from this year's ASCO meeting reshape decision-making across the prostate cancer spectrum, from the operating room to the metastatic setting.
Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Permission to Pause Treatment
By Peter Silberstein, MD
Four developments from this year's ASCO meeting reshape decision-making across the prostate cancer spectrum, from the operating room to the metastatic setting.
CAR-T Cell Therapy for Large B-Cell Lymphoma: Who, When, and Where to Deliver It
By Chenyu Lin, MD
CAR-T cell therapy for large B-cell lymphoma is expanding through broader patient eligibility, earlier treatment, head-to-head trials, and remote monitoring.
CAR-T Cell Therapy for Large B-Cell Lymphoma: Who, When, and Where to Deliver It
By Chenyu Lin, MD
CAR-T cell therapy for large B-cell lymphoma is expanding through broader patient eligibility, earlier treatment, head-to-head trials, and remote monitoring.
CAR-T Cell Therapy for Large B-Cell Lymphoma: Who, When, and Where to Deliver It
By Chenyu Lin, MD
CAR-T cell therapy for large B-cell lymphoma is expanding through broader patient eligibility, earlier treatment, head-to-head trials, and remote monitoring.
Pancreatic Cancer: A RAS Inhibitor Nearly Doubles Survival, and a KRAS Vaccine Shows Real Promise
By Weijing Sun, MD
Pancreatic cancer has been a difficult disease to move the needle on: median survival with first-line chemotherapy has hovered around six months for decades, and targeted therapy has largely unsuccess here despite working elsewhere.
Pancreatic Cancer: A RAS Inhibitor Nearly Doubles Survival, and a KRAS Vaccine Shows Real Promise
By Weijing Sun, MD
Pancreatic cancer has been a difficult disease to move the needle on: median survival with first-line chemotherapy has hovered around six months for decades, and targeted therapy has largely unsuccess here despite working elsewhere.
Pancreatic Cancer: A RAS Inhibitor Nearly Doubles Survival, and a KRAS Vaccine Shows Real Promise
By Weijing Sun, MD
Pancreatic cancer has been a difficult disease to move the needle on: median survival with first-line chemotherapy has hovered around six months for decades, and targeted therapy has largely unsuccess here despite working elsewhere.
Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance
By Moataz Ellithi, MD
Cellular therapy for blood cancers is moving in two directions at once: toward manufacturing CAR T-cells directly inside a patient's body rather than in a lab
Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance
By Moataz Ellithi, MD
Cellular therapy for blood cancers is moving in two directions at once: toward manufacturing CAR T-cells directly inside a patient's body rather than in a lab
Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance
By Moataz Ellithi, MD
Cellular therapy for blood cancers is moving in two directions at once: toward manufacturing CAR T-cells directly inside a patient's body rather than in a lab
Lymphoma and CLL at ASCO 2026: New Frontline and Relapsed-Setting Data
By Poornima Ramadas, MD
Lymphoma and CLL data at the 2026 ASCO Annual Meeting spanned the treatment continuum, from frontline diffuse large B-cell lymphoma (DLBCL) to relapsed/refractory disease across several lymphoma subtypes, to a striking early combination in frontline CLL.
Lymphoma and CLL at ASCO 2026: New Frontline and Relapsed-Setting Data
By Poornima Ramadas, MD
Lymphoma and CLL data at the 2026 ASCO Annual Meeting spanned the treatment continuum, from frontline diffuse large B-cell lymphoma (DLBCL) to relapsed/refractory disease across several lymphoma subtypes, to a striking early combination in frontline CLL.
Lymphoma and CLL at ASCO 2026: New Frontline and Relapsed-Setting Data
By Poornima Ramadas, MD
Lymphoma and CLL data at the 2026 ASCO Annual Meeting spanned the treatment continuum, from frontline diffuse large B-cell lymphoma (DLBCL) to relapsed/refractory disease across several lymphoma subtypes, to a striking early combination in frontline CLL.